
| Disease Domain | Count | 
|---|---|
| Endocrinology and Metabolic Disease | 3 | 
| Nervous System Diseases | 2 | 
| Neoplasms | 2 | 
| Top 5 Drug Type | Count | 
|---|---|
| Small molecule drug | 5 | 
| Chemical drugs | 2 | 
| Herbal medicine | 2 | 
| Target- | 
| Mechanism- | 
| Active Org. | 
| Originator Org.- | 
| Inactive Indication | 
| Drug Highest PhaseNDA/BLA | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
| Target- | 
| Mechanism- | 
| Originator Org. | 
| Active Indication | 
| Inactive Indication | 
| Drug Highest PhasePhase 2 | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
| Target | 
| Mechanism SIRT3 agonists | 
| Active Org. | 
| Originator Org. | 
| Active Indication | 
| Inactive Indication- | 
| Drug Highest PhasePreclinical | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
| Start Date01 May 2025 | 
| Sponsor / Collaborator | 
| Start Date15 Apr 2025 | 
| Sponsor / Collaborator | 
| Start Date01 Apr 2025 | 
| Sponsor / Collaborator | 

| Drug(Targets) | Indications | Global Highest Phase | 
|---|---|---|
| Qideng Mingmu Capsule | Macular Edema More | Phase 2 | 
| Hydroxysafflor Yellow A | Fibrosis, Liver More | Preclinical | 
| Forsythiaside A(  MAPK x NF-κB x PPAR x RXRs ) | Colitis More | Preclinical | 
| 2-APQC(  SIRT3 ) | Cardiomegaly More | Preclinical | 
| Ginsenoside Rb1(  DUSP1 x MFN2 x TMBIM6 x VDAC1 ) | Myocardial injury More | Preclinical | 





